ProCE Banner Activity

Phase II Trial of Lenalidomide and Eltrombopag for Low-Risk/Intermediate-Risk MDS

Slideset Download
Conference Coverage
Treatment with lenalidomide and/or eltrombopag yielded favorable outcomes in patients with low-risk/intermediate-risk MDS and symptomatic anemia or thrombocytopenia, including hematologic improvement in 35% and a median duration of response of 1.5 years.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation